4 Speculative Biotech and Biohealth Analyst Upgrades
It seems that analysts are taking the forefront and making calls on where the biopharma industry is going ahead of action by the Trump administration.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
The health care sector was in trouble over the past year, under fire from congressional hearings and politicians on the campaign trail. But 2017 could be different, with a new administration and new perspective that could lead to more positive trials, U.S. Food and Drug Administration (FDA) approvals and mergers and acquisitions.
It seems that analysts are taking the forefront and making calls on where the biopharma industry is going ahead of action by the Trump administration. 24/7 Wall St. has collected a few of the important calls on the day thus far and added some color on them.
We have included what analysts are saying about each stock, as well as a recent trading history and the consensus price target.
Alynylam Pharmaceuticals Inc. (NASDAQ: ALNY) was upgraded by JPMorgan to a Neutral rating, and the price target was raised to $53 from $50. The stock had previously closed at $38.16. Shares of Alynylam were trading down 3.0% at $37.01 midday Tuesday, with a consensus analyst price target of $63.36 and a 52-week trading range of $31.38 to $80.11.
Baird raised its rating on Amicus Therapeutics Inc. (NASDAQ: FOLD) to Outperform, while its price target saw a significant gain to $10 from $7. The prior close was $5.34. Shares were trading down 1.8% at $5.24. The consensus price target is $10.69, and a 52-week range is $4.41 to $9.83.
Citigroup upgraded Calithera Biosciences Inc. (NASDAQ: CALA) to Neutral from Sell. The price target was also raised to $5 from $1, compared with a prior close of $4.40. Calithera Biosciences was up 5.7% at $4.65, within a 52-week range of $2.20 to $6.87. The consensus analyst target is $8.25.
Needham issued a Buy rating for GenMark Diagnostics Inc. (NASDAQ: GNMK) and raised its price target to $15, up from $13. The stock had previously closed at $12.48. The shares traded down fractionally to $12.49. The 52-week range is $4.20 to $13.43. The consensus price target is $14.90.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
